CCL5 and neoplasm: Among them, the expression of anti-PD-1 antibody and IL-12 was consistent with the expression profile reported elsewhere (8) and the constant expression of CCL5 can last for 3 weeks in vivo. In this study, we just evaluated T7011-mediated CAR targets and their anti-tumor activity combined with CAR T cell treatment in immunodeficient mice.